Navigation Links
Make Lashes Longer, Thicker, and Darker with Latisse™
Date:2/12/2009

Mascara may not be the only thing that can be using to enhance eyelashes. Latisse™, a revolutionary new treatment for eyelash growth has arrived. Latisse™ was developed through years of research by Allergan, a pharmaceutical leader with over 60 years of expertise in prescription eye care products.

Beverly Hills, CA (PRWEB) February 12, 2009 -- Latisse™ (bimatoprost-ophthalmic-solution) 0.03%, approved by the U.S. Food and Drug Administration (FDA) in 2008, is a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. Prior to its FDA approval, Allergan conducted a 16 week clinical trial with approximately 280 volunteers to assess the safety and efficacy of Latisse™. The results exceeded expectations. Participants experienced lashes 25 percent longer, 106 percent thicker and 18 percent darker.

The story of Latisse unexpectedly began in ophthalmology offices and the treatment of glaucoma patients. A new class of medications known as prostamides had been developed to lower intraocular eye pressure and doctors noticed a surprising side effect: the prostamides also grew hair. Allergan produced Lumigan (the trade name for ophthalmic formulated bimatoprost solution) quickly became the most popular prostamide. Products such as Revitalash and Age Intervention were the first to hit the market. However, because of purported patent infringements, the makers of Age Intervention were forced to cease production. Their replacement product Marini Lash does not contain bimatoprost and as result is considered by many to be less effective than Latisse™.

"After using the product, my eyelashes really stand out. I get compliments all the time and it feels great! Everyone wants to know my secret. People even ask if I am wearing false eyelashes. I feel more confident knowing this product, unlike other lash growth products on the market, is FDA-approved. I will absolutely tell all of my friends (and anyone who asks) about this new lash growth product," states Lisa, an Allergan clinical study test subject.    

Available only by prescription, Epione is among the first medical offices to carry Latisse™. According to Epione's Medical Director, Dr. Simon Ourian, users can expect to grow longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain this effect, continued treatment with Latisse™ is required. If use of Latisse™ is discontinued, eyelashes will gradually return to their pre-treatment state over a period of weeks to months (the average eyelash follicle cycle).

"Clinical studies have shown that Latisse™ works well. Virtually everyone who has used it has seen great results. Until now people looking for longer eyelash had to apply cosmetics such as mascara or glue false eyelashes onto their eyelids. Now with Latisse Epione is proud to offer our patients a new option for making their eyelashes longer," says Dr. Ourian.

Dr. Ourian's Epione Medical Corporation, located in Beverly Hills Golden Triangle, is among the most comprehensive and state-of-the-art laser and aesthetic surgery centers. Dr. Ourian has been a pioneer for laser technology and non-invasive aesthetic procedures such as BOTOX®, Restylane, Radiesse and Sculptra. These treatments are used for correction or reversal of a variety of conditions such as acne, acne scars, skin discoloration, wrinkles, stretch marks, varicose veins, unwanted hair, and tattoos, cellulite, and tens of others. For further information please contact 310-271-6506 or visit www.epione.com

###

Read the full story at http://www.prweb.com/releases/latisselongerlashes/allerganeyes/prweb1972044.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Flaxseed May Relieve Hot Flashes
2. From Hot Flashes to Breast Cancer: ZRT Labs Hormone Testing Catches On As Women Consider Safer, More Natural Options.
3. News Flash on Hot Flashes: Soy Can Turn Down the Heat
4. Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes
5. Hot Flashes Not Always to Blame for Sleep Problems in Menopausal Women, Reports the Harvard Womens Health Watch
6. Cool new treatment for hot flashes in breast cancer survivors
7. Cool New Treatment for Hot Flashes in Breast Cancer Survivors
8. Hot Flashes Reduced by Neck Injection
9. Hot flashes underreported and linked to forgetfulness
10. Menopause: Hot Flashes Can Be Reduced 90% without Hormones
11. Hot Flashes, Night Sweats a Good Sign for Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Make Lashes Longer, Thicker, and Darker with Latisse™
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in the safety of your ... drownings during the summer. While most of us assume this type of accident will ... Very few people are taking the time to learn how to respond effectively or ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... announce the ATA 2017 President’s Awards recipients, comprised of organizations and individuals ... delivery. , The ATA 2017 President’s Awards recognize individuals and organizations ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may ... pelvic conditions and has helped many women become pregnant upon treating their diagnosis. ... office-based and simple outpatient evaluations. We can provide the necessary information to ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor ... I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: